Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEI Pharma Rides Wave Of Interest in AML

Executive Summary

MEI Pharma CEO Dan Gold explains Phase III plans for the oral HDAC inhibitor pracinostat in acute myeloid leukemia and why there is still room in the market for a new PI3 kinase inhibitor like MEI-401 in B-cell malignancies in an interview at the Biotech Showcase.

You may also be interested in...



Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US

Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133229

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel